Just in time to as­sure a de­ci­sion be­fore CVR dead­line, Bris­tol My­ers Squibb files NDA for Cel­gene/blue­bird CAR-T

A new CAR-T ther­a­py may be com­ing. And maybe $9 per share for Cel­gene in­vestors, too.

Bris­tol My­ers Squibb an­nounced they sub­mit­ted an NDA for the mul­ti­ple myelo­ma “ide-cel” CAR-T ther­a­py Cel­gene de­vel­oped in part­ner­ship with blue­bird. The ther­a­py is one of the three that has to be ap­proved to un­lock the BMS-Cel­gene con­tin­gent val­ue agree­ment that would give share­hold­ers of the ab­sorbed NJ com­pa­ny $9 per share. The first, ozan­i­mod, was ap­proved last week. The sec­ond, a CAR-T treat­ment for non-Hodgkin’s lym­phoma called liso-cel, was sub­mit­ted to the FDA in De­cem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.